NO20040680D0 - New dihydropterinone processes for their preparation and their use as a drug - Google Patents

New dihydropterinone processes for their preparation and their use as a drug

Info

Publication number
NO20040680D0
NO20040680D0 NO20040680A NO20040680A NO20040680D0 NO 20040680 D0 NO20040680 D0 NO 20040680D0 NO 20040680 A NO20040680 A NO 20040680A NO 20040680 A NO20040680 A NO 20040680A NO 20040680 D0 NO20040680 D0 NO 20040680D0
Authority
NO
Norway
Prior art keywords
dihydropterinone
drug
processes
preparation
new
Prior art date
Application number
NO20040680A
Other languages
Norwegian (no)
Other versions
NO20040680L (en
NO328804B1 (en
Inventor
Eckhart Bauer
Norbert Redemann
Thorsten Lehmann-Lintz
Gerald Pohl
Christian Eickmeier
Matthias Hoffmann
Gisela Schnapp
Matthias Grauert
Steffen Breitfelder
Martin Steegmaier
Jens Juergen Quant
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20040680D0 publication Critical patent/NO20040680D0/en
Publication of NO20040680L publication Critical patent/NO20040680L/en
Publication of NO328804B1 publication Critical patent/NO328804B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to novel dihydropteridinones of general formula (I), wherein the groups X, R<1>, R<2>, R<3>, R<4>, R<5> and R<7> are defined as per the claims and the description, to the isomers thereof, to a method for producing said dihydropteridinones and to the use thereof as medicaments.
NO20040680A 2001-09-04 2004-02-16 New dihydropterinones, methods for their preparation and their use NO328804B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10143272 2001-09-04
PCT/EP2002/009728 WO2003020722A1 (en) 2001-09-04 2002-08-30 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments

Publications (3)

Publication Number Publication Date
NO20040680D0 true NO20040680D0 (en) 2004-02-16
NO20040680L NO20040680L (en) 2004-02-16
NO328804B1 NO328804B1 (en) 2010-05-18

Family

ID=7697637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040680A NO328804B1 (en) 2001-09-04 2004-02-16 New dihydropterinones, methods for their preparation and their use

Country Status (30)

Country Link
EP (1) EP1427730B1 (en)
JP (1) JP3876254B2 (en)
KR (1) KR100955589B1 (en)
CN (1) CN1551881A (en)
AR (1) AR036586A1 (en)
AT (1) ATE332898T1 (en)
AU (1) AU2002337047B2 (en)
BR (1) BRPI0212137A2 (en)
CA (1) CA2458699C (en)
CO (1) CO5560575A2 (en)
CY (1) CY1105337T1 (en)
DE (1) DE50207522D1 (en)
DK (1) DK1427730T3 (en)
EA (1) EA007062B1 (en)
EC (1) ECSP045003A (en)
ES (1) ES2268093T3 (en)
HR (1) HRP20040213A2 (en)
HU (1) HUP0401293A3 (en)
IL (2) IL160440A0 (en)
MX (1) MXPA04002067A (en)
MY (1) MY129751A (en)
NO (1) NO328804B1 (en)
NZ (1) NZ531928A (en)
PL (1) PL369740A1 (en)
PT (1) PT1427730E (en)
RS (1) RS51012B (en)
UA (1) UA76512C2 (en)
UY (1) UY27427A1 (en)
WO (1) WO2003020722A1 (en)
ZA (1) ZA200401365B (en)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
CA2378241A1 (en) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
EA008778B1 (en) * 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Dihydropteridinones, method for the production and use thereof in the form of drugs
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (en) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1632493A1 (en) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridine derivatives, methods for their preparation and their use as drugs
CA2578560A1 (en) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for the production thereof, and use thereof as a medicament
DE102004058337A1 (en) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
JP2009503014A (en) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
DE602007008837D1 (en) 2006-02-14 2010-10-14 Vertex Pharma AS PROTEIN KINASE INHIBITORS USEFUL DYHYDRODIAZEPINE
WO2007135374A1 (en) * 2006-05-19 2007-11-29 Astrazeneca Ab Dihydropteridine compounds as anti proliferative agents
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
NZ576278A (en) * 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
KR101157848B1 (en) * 2007-03-22 2012-07-11 다케다 야쿠힌 고교 가부시키가이샤 Substituted pyrimidodiazepines useful as plk1 inhibitors
WO2008157235A1 (en) * 2007-06-13 2008-12-24 University Of Virginia Patent Foundation Rsk inhibitors as anti-septicemia agents
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2215091B1 (en) * 2007-12-04 2016-03-30 Nerviano Medical Sciences S.r.l. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
JP5593234B2 (en) 2008-03-11 2014-09-17 ユニバーシティー ヘルス ネットワーク Methods of treating cancer using neuropeptide Y5R (NPY5R) antagonists
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807452D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd PLK inhibitors
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
KR101787309B1 (en) 2008-12-09 2017-10-18 길리애드 사이언시즈, 인코포레이티드 Modulators of toll-like receptors
ES2661850T3 (en) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Toll type receiver modulators
CN102020643A (en) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 dihydropteridine ketone derivative, and preparation method and medicinal application thereof
AU2010298190A1 (en) 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
JP2013505927A (en) 2009-09-25 2013-02-21 バーテックス ファーマシューティカルズ インコーポレイテッド Method for preparing pyrimidine derivatives useful as protein kinase inhibitors
EP3091021B1 (en) 2009-10-26 2019-08-28 Signal Pharmaceuticals, LLC Methods of synthesis and purification of heteroaryl compounds
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
AU2010336509A1 (en) 2009-12-23 2012-07-19 Elan Pharmaceuticals, Inc Pteridinones as inhibitors of polo-like kinase
EP2536725B1 (en) 2010-02-17 2015-10-28 Boehringer Ingelheim International GmbH Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
TWI708605B (en) 2011-10-19 2020-11-01 標誌製藥公司 Treatment of cancer with tor kinase inhibitors
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EA026390B1 (en) 2011-12-02 2017-04-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, SOLID FORMS THEREOF AND METHODS OF THEIR USE
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
EP2817029B1 (en) 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
JP6052527B2 (en) * 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone I
JP6072308B2 (en) * 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone II
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2908830C (en) 2013-04-17 2021-12-07 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
AU2014253978B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
MX2015014455A (en) 2013-04-17 2016-07-21 Signal Pharm Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-yl amino)phenyl)acrylamide for treating cancer.
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6401250B2 (en) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー 7- (6- (2-hydroxypropan-2-yl) pyridin-3-yl) -1-((trans) -4-methoxycyclohexyl) -3,4-dihydropyrazino [2,3-b] pyrazine-2 (1H) -one, pharmaceutical composition thereof in solid form, and method of use thereof
WO2015004075A1 (en) * 2013-07-09 2015-01-15 Bayer Pharma Aktiengesellschaft Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones
BR112016001457A2 (en) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CN103664845B (en) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 The preparation method of amino-2, the 3-Dihydrobenzofuranes-4-formic acid of a kind of Plk kinase inhibitor drug intermediate 7-
JP2017504653A (en) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Diaminopyrimidine benzenesulfone derivatives and uses thereof
JP2017504651A (en) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Use of diazepan derivatives
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015193228A1 (en) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-protein inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with para-substituted aromatic amino- or ether groups
WO2015193229A1 (en) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-protein inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with meta-substituted aromatic amino- or ether groups
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
US9623028B2 (en) 2014-07-14 2017-04-18 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
EA201790369A1 (en) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. SOLID FORMS OF THOUGH-RECEPTOR MODULATOR
EA201790373A1 (en) 2014-09-16 2017-08-31 Джилид Сайэнс, Инк. METHODS OF OBTAINING MODULATORS OF TOLL-SIMILAR RECEPTORS
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
RU2750164C2 (en) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Cyanothienotriazolodiazepines and methods for their use
KR20180051576A (en) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. Acetamide thienotriazolol diazepines and their uses
WO2017091673A2 (en) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibtors and uses thereof
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
BR112019027402A2 (en) 2017-06-22 2020-07-07 Celgene Corporation treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus
CA3080941A1 (en) * 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Nek inhibitors and methods of use
CA3097774A1 (en) * 2018-04-24 2019-10-31 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
CN108610343A (en) * 2018-06-12 2018-10-02 杨文思 A kind of epidermal growth factor receptor inhibitor and its synthetic method for treating cancer
WO2020033823A1 (en) * 2018-08-10 2020-02-13 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (en) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 MST1 kinase inhibitors and uses thereof
CN113637017B (en) * 2021-08-12 2024-03-26 中国药科大学 Compound containing dihydropterin structure, its preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645152B1 (en) * 1989-03-30 1991-05-31 Lipha 3H-PTERIDINONES-4, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM
CA2029651C (en) * 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
SK3542002A3 (en) * 1999-09-15 2003-04-01 Warner Lambert Co Pteridinones as kinase inhibitors
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
NZ531928A (en) 2005-10-28
CA2458699A1 (en) 2003-03-13
IL160440A0 (en) 2004-07-25
HUP0401293A2 (en) 2004-10-28
KR100955589B1 (en) 2010-04-30
HUP0401293A3 (en) 2008-03-28
EP1427730A1 (en) 2004-06-16
AR036586A1 (en) 2004-09-22
ES2268093T3 (en) 2007-03-16
UA76512C2 (en) 2006-08-15
WO2003020722A1 (en) 2003-03-13
AU2002337047B8 (en) 2003-03-18
JP3876254B2 (en) 2007-01-31
HRP20040213A2 (en) 2005-02-28
ECSP045003A (en) 2004-04-28
UY27427A1 (en) 2003-03-31
DK1427730T3 (en) 2006-11-06
ZA200401365B (en) 2005-05-27
CO5560575A2 (en) 2005-09-30
CN1551881A (en) 2004-12-01
RS51012B (en) 2010-10-31
PT1427730E (en) 2006-11-30
CY1105337T1 (en) 2010-03-03
NO20040680L (en) 2004-02-16
EA007062B1 (en) 2006-06-30
IL160440A (en) 2009-09-01
AU2002337047B2 (en) 2008-01-10
MY129751A (en) 2007-04-30
YU27304A (en) 2006-08-17
JP2005501904A (en) 2005-01-20
KR20040029465A (en) 2004-04-06
PL369740A1 (en) 2005-05-02
ATE332898T1 (en) 2006-08-15
CA2458699C (en) 2010-10-19
MXPA04002067A (en) 2004-06-07
EA200400368A1 (en) 2004-12-30
NO328804B1 (en) 2010-05-18
DE50207522D1 (en) 2006-08-24
BRPI0212137A2 (en) 2016-06-28
EP1427730B1 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
NO20040680D0 (en) New dihydropterinone processes for their preparation and their use as a drug
DK1421074T3 (en) New connections
DK1599478T3 (en) Dihydropteridinones, their method of preparation and their use as a drug
CO5611065A2 (en) DIFLUOROMETILTIAZOLILCARBOXANILIDAS
WO2004014902A3 (en) Compounds having an activity at metabotropic glutamate receptors
NO20040314L (en) New connections
SE0200920D0 (en) Novel compounds
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
BRPI0318811B8 (en) spirocyclic cyclohexanol derivatives
DK1506185T3 (en) Compounds and their use as 5-HT inhibitors
NO20026064D0 (en) New connections
SE0103836D0 (en) Novel compounds
NO20050612L (en) Pyrrolidine derivatives as oxytocin antagonists
UY27410A1 (en) NEW CRYSTAL CRUDE FORMS
SE0101038D0 (en) Novel compounds
ATE409695T1 (en) FURAN CARBOXAMIDES
NO20026081L (en) New connections
NO992731D0 (en) New Substituted Tetrahydropyridine Compounds, Methods of Preparing Them, and Pharmaceutical Compounds
MXPA04001855A (en) Derivatives of c2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments.
NO20000199D0 (en) Medications containing polyhydroxybutylpyrazines, new polyhydroxybutylpyrazines and their preparation
BR0309526A (en) Methylthiophenecarboxanilides
EA200300771A1 (en) NEW SALT BENZOILGUANIDINE
HUP0401895A2 (en) N-formyl derivatives of paroxetine, process for their preparation and pharmaceutical compositions containing them
MXPA04001856A (en) C2-substituted indane-1-ols and their derivatives, method for their production and their use as medicaments.
MXPA04001852A (en) C2-substituted indane-1-ones and their derivatives, method for their production and their use as medicaments.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees